4746 Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Formosa Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$79.10 |
| 52 Week High | NT$121.00 |
| 52 Week Low | NT$78.60 |
| Beta | 0.76 |
| 11 Month Change | -14.49% |
| 3 Month Change | -14.49% |
| 1 Year Change | -18.95% |
| 33 Year Change | 38.05% |
| 5 Year Change | 83.74% |
| Change since IPO | -13.93% |
Recent News & Updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)
Sep 20
Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings Quality
May 22Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share Price
Apr 19Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt Burden
Apr 19Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?
Mar 16What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 08Formosa Laboratories (TPE:4746) Is Making Moderate Use Of Debt
Jan 11
Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?
Dec 13Shareholder Returns
| 4746 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -8.3% | 2.0% | -0.5% |
| 1Y | -19.0% | 8.0% | 28.4% |
Return vs Industry: 4746 underperformed the TW Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: 4746 underperformed the TW Market which returned 28.4% over the past year.
Price Volatility
| 4746 volatility | |
|---|---|
| 4746 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.1% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4746 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4746's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | n/a | Chen-Yu Cheng | www.formosalab.com |
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. It also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services.
Formosa Laboratories, Inc. Fundamentals Summary
| 4746 fundamental statistics | |
|---|---|
| Market cap | NT$9.51b |
| Earnings (TTM) | NT$392.86m |
| Revenue (TTM) | NT$4.59b |
24.2x
P/E Ratio2.1x
P/S RatioIs 4746 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4746 income statement (TTM) | |
|---|---|
| Revenue | NT$4.59b |
| Cost of Revenue | NT$2.58b |
| Gross Profit | NT$2.01b |
| Other Expenses | NT$1.62b |
| Earnings | NT$392.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.27 |
| Gross Margin | 43.88% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 43.2% |
How did 4746 perform over the long term?
See historical performance and comparison